Chris Arthur

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2003 · 766 citations · Full text

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2002 · 657 citations · Full text

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Timothy P. Hughes, Susan Branford, Deborah L. White et al. · Blood · 2008 · 177 citations · Full text

Intravenous Itraconazole Followed by Oral Itraconazole in the Treatment of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies, Chronic Granulomatous Disease, or AIDS

Denis Caillot, Harry P. Bassaris, Allison McGeer et al. · Clinical Infectious Diseases · 2001 · 160 citations · Full text

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Susan Branford, Zbigniew Rudzki, Andrew Harper et al. · Leukemia · 2003 · 157 citations

Chronic Phase, Hematological Malignancy, Chronic Myeloid Leukemia +10